Stocks Overview

LAST PRICE
0.3327
TODAY'S CHANGE (%)
Trending Down-0.0583 (-14.9105%)

Bid / Lots
0.3200/ 3
Ask / Lots
0.3400/ 1
Open / Previous Close
0.3570 / 0.3910
Day Range
Low 0.3100
High 0.3600
52 Week Range
Low 0.3100
High 5.4800
Volume
1,546,553
below average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TSX Comp
TSX Venture
DJIA
S&P 500
NASDAQ

Price Comparison Graph. See accessible table below

1 Day Comparison Chart Accessibility Table. Thursday's close: 0.391
Time	Volume	VRPX
09:32 ET	28526	0.36
09:33 ET	35563	0.3468
09:35 ET	45648	0.337
09:37 ET	7591	0.346
09:39 ET	16612	0.346
09:44 ET	100	0.346
09:46 ET	1648	0.346
09:48 ET	7244	0.345
09:50 ET	938	0.35
09:51 ET	1304	0.3451
09:53 ET	3600	0.3452
09:57 ET	4970	0.35
10:00 ET	270	0.3453
10:02 ET	2000	0.35
10:04 ET	1180	0.348
10:06 ET	5623	0.34885
10:08 ET	2506	0.3467
10:09 ET	400	0.3497
10:11 ET	300	0.3497
10:13 ET	333731	0.3186
10:15 ET	8765	0.3399
10:18 ET	3928	0.3397
10:20 ET	4429	0.326
10:22 ET	2300	0.325
10:24 ET	15583	0.331
10:26 ET	1399	0.326
10:27 ET	14306	0.33
10:29 ET	4731	0.3395
10:31 ET	13637	0.336
10:33 ET	4000	0.3399
10:36 ET	1900	0.3201
10:40 ET	10755	0.3241
10:42 ET	4608	0.33939
10:45 ET	100	0.3394
10:49 ET	2200	0.335
10:51 ET	610	0.3301
10:54 ET	2900	0.3393
10:56 ET	1301	0.3393
11:00 ET	200	0.3392
11:03 ET	4100	0.3392
11:05 ET	4200	0.3268
11:09 ET	297	0.337
11:12 ET	400	0.33
11:18 ET	1300	0.33
11:20 ET	830	0.3331
11:21 ET	200	0.3331
11:23 ET	3632	0.3311
11:25 ET	3144	0.33
11:27 ET	5126	0.3354
11:30 ET	8848	0.33
11:32 ET	112	0.3301
11:34 ET	100	0.3327
11:36 ET	479	0.332721
11:38 ET	5500	0.3354
11:41 ET	3500	0.3354
11:43 ET	10986	0.3354
11:45 ET	23247	0.3301
11:50 ET	1400	0.332
11:52 ET	9659	0.3301
11:54 ET	400	0.3365
11:56 ET	19087	0.34
11:57 ET	5550	0.338
11:59 ET	5110	0.34
12:06 ET	200	0.3331
12:08 ET	1000	0.34
12:10 ET	100	0.34
12:12 ET	1600	0.34
12:14 ET	150	0.3435
12:15 ET	436	0.3407
12:17 ET	2126	0.3469
12:19 ET	400	0.3425
12:24 ET	1630	0.3419
12:26 ET	800	0.3385
12:28 ET	130	0.3385
12:30 ET	100	0.342
12:42 ET	6000	0.335
12:50 ET	268	0.3379
12:53 ET	200	0.342
01:02 ET	200	0.3406
01:04 ET	6573	0.33995
01:06 ET	828	0.3379
01:08 ET	35364	0.335
01:18 ET	15635	0.333
01:20 ET	1000	0.333
01:24 ET	1750	0.3331
01:29 ET	4394	0.342499
01:33 ET	7906	0.342
01:36 ET	500	0.3425
01:38 ET	500	0.3377
01:47 ET	7485	0.3391
01:49 ET	7906	0.3334
01:51 ET	2555	0.3315
01:54 ET	100	0.3367
02:03 ET	780	0.3334
02:07 ET	148	0.34
02:12 ET	4513	0.34
02:14 ET	2632	0.3366
02:16 ET	2308	0.3334
02:18 ET	9700	0.339999
02:20 ET	1000	0.337809
02:25 ET	250	0.3351
02:27 ET	435	0.3345
02:34 ET	902	0.33
02:36 ET	2000	0.3301
02:41 ET	4000	0.335
02:43 ET	300	0.335
02:45 ET	284	0.3331
02:50 ET	698	0.3378
02:54 ET	250	0.331
02:57 ET	800	0.332
02:59 ET	1000	0.3378
03:03 ET	720	0.3344
03:06 ET	100	0.3378
03:08 ET	8291	0.3361
03:10 ET	6725	0.3377
03:12 ET	2800	0.3377
03:14 ET	300	0.337
03:15 ET	243	0.332
03:17 ET	991	0.332
03:19 ET	390	0.335
03:21 ET	31100	0.3366
03:24 ET	200	0.3377
03:26 ET	3500	0.3372
03:28 ET	110	0.3377
03:30 ET	600	0.335
03:35 ET	356	0.3364
03:37 ET	12223	0.3378
03:39 ET	609	0.335
03:46 ET	2596	0.3394
03:48 ET	6094	0.34
03:50 ET	5728	0.3434
03:51 ET	20753	0.3397
03:53 ET	3726	0.34
03:55 ET	18375	0.3425
03:57 ET	11223	0.336
04:00 ET	18042	0.3327

Data delayed at least 15 minutes.

Nov 22, 2024
- Virpax Announces Positive Results for the Swine Model Dose Range Finding Study for Probudur(TM), from 8:30AM ET on Friday Nov 22, 2024 by Dow Jones
  8:30AM ET on Friday Nov 22, 2024 by Dow Jones
Nov 21, 2024
- DJ Virpax Pharma Gets Government Cooperation Deal Extension, from 4:41PM ET on Thursday Nov 21, 2024 by Dow Jones
  4:41PM ET on Thursday Nov 21, 2024 by Dow Jones
- Virpax Announces Agreement with the U.S. Department of Health and Human Services for the Developmental Extension for NES100 Towards IND for Acute and Chronic Non-Cancer Pain Alternative, from 4:05PM ET on Thursday Nov 21, 2024 by Dow Jones
  4:05PM ET on Thursday Nov 21, 2024 by Dow Jones
Nov 18, 2024
- Spartan Capital Securities, LLC Serves as Sole Placement Agent in Virpax Pharmaceuticals, Inc.'s $5.0 Million Public Offering, from 10:23AM ET on Monday Nov 18, 2024 by Dow Jones
  10:23AM ET on Monday Nov 18, 2024 by Dow Jones
Nov 15, 2024
- Virpax Pharmaceuticals, Inc. Announces Closing of $5.0 Million Public Offering of Common Stock and Pre-Funded Warrants, from 4:09PM ET on Friday Nov 15, 2024 by Dow Jones
  4:09PM ET on Friday Nov 15, 2024 by Dow Jones

0 New Today

Industry Peers Overview Table
Company sortable	Market Cap sortable	P/E Ratio (TTM) sortable	EPS Growth (5yr) sortable
United StatesVRPX Virpax Pharmaceuticals Inc	2.7M	0.0x	---
United StatesBPTH Bio Path Holdings Inc	2.7M	-0.1x	---
United StatesSHPH Shuttle Pharmaceuticals Holdings Inc	2.7M	-0.2x	---
United StatesQRON Qrons Inc	2.6M	-6.4x	---
United StatesSCNI Scinai Immunotherapeutics Ltd	2.8M	41.3x	---
United StatesBPTSY Biophytis SA	2.4M	0.0x	---
As of 2024-12-07

Virpax Pharmaceuticals, Inc. is a preclinical-stage pharmaceutical company. The Company is focused on developing novel and proprietary drug delivery systems across various pain indication. Its drug-delivery systems and drug-releasing technologies being developed are focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system (CNS) disorders to enhance patients’ quality of life. Its portfolio consists of multiple preclinical stage product candidates: Epoladerm, Probudur, Envelta, AnQlar and NobrXiol. Probudur is a single injection liposomal bupivacaine formulation being developed to manage post-operative pain. Envelta is an intranasal molecular envelope enkephalin formulation being developed to manage acute and chronic pain, including pain associated with cancer. The NobrXiol is being developed for the nasal delivery of a pharmaceutical-grade cannabidiol (CBD) for the management of rare pediatric epilepsy.

Contact Information

Headquarters: 1055 Westlakes Drive, Suite 300BERWYN, PA, United States 19312
Phone: 610-727-4597
Fax: 302-636-5454

Executives

Chief Executive Officer, Director: Jatinder Dhaliwal
Chief Financial Officer: Usama Chaudhry
Chief Scientific Officer: Sheila Mathias
Vice President, Director: Katharyn Field
Director: Judy Su

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Skip section

INK Company InsiderDetailed daily analysis of insider activity and holdings for stocks and income trusts listed in Canada, based on filings from SEDI®.

Fundamentals Table
Market Cap	$2.7M
Revenue (TTM)	$0.00
Shares Outstanding	8.1M
Dividend Yield	0.00%
Annual Dividend Rate	---
Ex-Dividend Date	01-01-01
Pay Date	01-01-01
Beta	0.90
EPS	$-8.82
Book Value	$1.65
P/E Ratio	0.0x
Price/Sales (TTM)	---
Price/Cash Flow (TTM)	---
Operating Margin	---

*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.

Virpax Pharmaceuticals Inc
NASDAQ:VRPXUnited States
NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

Search Criteria

Charts

Recent News

Nov 22, 2024

Virpax Announces Positive Results for the Swine Model Dose Range Finding Study for Probudur(TM), from 8:30AM ET on Friday Nov 22, 2024 by Dow Jones

Nov 21, 2024

DJ Virpax Pharma Gets Government Cooperation Deal Extension, from 4:41PM ET on Thursday Nov 21, 2024 by Dow Jones

Virpax Announces Agreement with the U.S. Department of Health and Human Services for the Developmental Extension for NES100 Towards IND for Acute and Chronic Non-Cancer Pain Alternative, from 4:05PM ET on Thursday Nov 21, 2024 by Dow Jones

Nov 18, 2024

Spartan Capital Securities, LLC Serves as Sole Placement Agent in Virpax Pharmaceuticals, Inc.'s $5.0 Million Public Offering, from 10:23AM ET on Monday Nov 18, 2024 by Dow Jones

Nov 15, 2024

Virpax Pharmaceuticals, Inc. Announces Closing of $5.0 Million Public Offering of Common Stock and Pre-Funded Warrants, from 4:09PM ET on Friday Nov 15, 2024 by Dow Jones

Biotechnology Industry Peers

Company Information

Contact Information

Executives

Ratings

Reports

Fundamentals

Calendar